Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) EBT (2016 - 2025)

Fortress Biotech has reported EBT over the past 13 years, most recently at -$6.2 million for Q4 2025.

  • Quarterly results put EBT at -$6.2 million for Q4 2025, up 76.08% from a year ago — trailing twelve months through Dec 2025 was -$55.0 million (up 52.39% YoY), and the annual figure for FY2025 was -$33.5 million, up 72.18%.
  • EBT for Q4 2025 was -$6.2 million at Fortress Biotech, down from $8.9 million in the prior quarter.
  • Over the last five years, EBT for FBIO hit a ceiling of $8.9 million in Q3 2025 and a floor of -$61.9 million in Q4 2021.
  • Median EBT over the past 5 years was -$35.8 million (2024), compared with a mean of -$35.5 million.
  • Biggest five-year swings in EBT: tumbled 157.6% in 2021 and later surged 133.25% in 2025.
  • Fortress Biotech's EBT stood at -$61.9 million in 2021, then grew by 7.86% to -$57.0 million in 2022, then surged by 49.81% to -$28.6 million in 2023, then rose by 9.18% to -$26.0 million in 2024, then surged by 76.08% to -$6.2 million in 2025.
  • The last three reported values for EBT were -$6.2 million (Q4 2025), $8.9 million (Q3 2025), and -$35.9 million (Q2 2025) per Business Quant data.